Thursday, August 27, 2026

Corporate Risk Assessment

2 articles

IDEX Faces Catastrophic Export Control Risk From Mott Corp. Acquisition

IDEX Faces Catastrophic Export Control Risk From Mott Corp. Acquisition

IDEX's September 2024 acquisition of Mott Corp. has introduced a regulatory exposure rated catastrophic in severity. Mott's advanced porous metal and filtration technologies overlap with product categories governed by U.S. export control law, including EAR and ITAR. IDEX's global operations create pathways through which controlled technologies could reach restricted parties or sanctioned jurisdictions.

LM Salvado
Alliance Resource Partners faces stranded asset risk as coal phase-out accelerates across four-state footprint

Alliance Resource Partners faces stranded asset risk as coal phase-out accelerates across four-state footprint

Alliance Resource Partners, L.P., the Tulsa-based coal MLP, confronts medium-probability catastrophic risk from energy transition rendering its Illinois, Indiana, Kentucky, and West Virginia mining complexes obsolete. The assessment carries 70% confidence as utilities accelerate coal plant retirements ahead of schedule. Stranded asset exposure threatens the partnership's debt service capacity and unitholder distributions.

ViaNews Editorial Team (Finance)
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com